Team:SYSU-China/Project/Overview

From 2013.igem.org

(Difference between revisions)
(Created page with "<html> <head> <link rel="stylesheet" href="https://2013.igem.org/Team:SYSU-China/main.css?action=raw&ctype=text/css" type="text/css" /> <style type="text/css"> body {background-c...")
 
(6 intermediate revisions not shown)
Line 38: Line 38:
<h1>Overview: iPSCs Safeguard</h1>
<h1>Overview: iPSCs Safeguard</h1>
<p>
<p>
-
<strong>To live or not to live?</strong> This time, why not let cells answer this problem and select their fates automatically?
+
<strong>To live or not to live?</strong> This time, why not let cells answer this question and select their fates automatically?
</p>
</p>
<br /><img src=" https://static.igem.org/mediawiki/2013/9/90/Overview1.png " width="700" /><br />
<br /><img src=" https://static.igem.org/mediawiki/2013/9/90/Overview1.png " width="700" /><br />
<p>
<p>
-
This summer, iGEM team of SYSU-China comes up with a new strategy to solve minimize the tumorigenesis risks of iPSCs: We designed a device which can <strong>select the right kind of cells from induced cell mass and retain selection pressure to remove cancerous cells.</strong> During differentiation, wrong kinds of or undifferentiated cells will undergo senescence and the transferred cells can be cultured and brought into further usage. After cells are transplanted into organ of patient, the spontaneous cancerous cells can be cleared.  
+
This summer, iGEM team of SYSU-China came up with a new strategy to minimize the tumorigenesis risks of iPSCs: We designed a device which can <strong>select the right kinds of cells from induced cell mass and retain selection pressure to remove cancerous cells in the long term.</strong> During differentiation, undifferentiated cells or wrong kinds of differentiated cells will undergo apoptosis and the transferred cells can be cultured and brought into further usage. After cells are transplanted into patient’s body, the spontaneous cancerous cells can be killed and cleared.  
</p>
</p>
<p>
<p>
-
We have chosen <strong>hepatocytes</strong> and its highly expressed miR-122 to test this idea. For convenience, we have alter promoter of gene into EF1a which will not be silenced in pluripotent stage with a Tet-off switch to turn on the circuit at the right time. Patients suffering from chronic end-stage liver disease are currently receiving inadequate treatment due to the lack of organ donors for transplantation. There are several ways to convert iPS cells into hepatocytes available. We hope that our device aid the development and of iPS technology.  
+
We have chosen <strong>hepatocytes</strong>, a type of normal liver cell, and its highly expressed miR-122 to achieve this idea. In order to accurately control our device at the right time, we introduced a manually-indusing switch, tet-off system, to our project. We altered promoter of gene into EF-1α which would not be silenced in pluripotent stage. There are several ways to convert iPS cells into hepatocytes available. We hope that our device could promote the development and clinical application of iPSC technology.  
</p>
</p>

Latest revision as of 02:07, 31 July 2014

ipsc

Project/Overview

Overview: iPSCs Safeguard

To live or not to live? This time, why not let cells answer this question and select their fates automatically?



This summer, iGEM team of SYSU-China came up with a new strategy to minimize the tumorigenesis risks of iPSCs: We designed a device which can select the right kinds of cells from induced cell mass and retain selection pressure to remove cancerous cells in the long term. During differentiation, undifferentiated cells or wrong kinds of differentiated cells will undergo apoptosis and the transferred cells can be cultured and brought into further usage. After cells are transplanted into patient’s body, the spontaneous cancerous cells can be killed and cleared.

We have chosen hepatocytes, a type of normal liver cell, and its highly expressed miR-122 to achieve this idea. In order to accurately control our device at the right time, we introduced a manually-indusing switch, tet-off system, to our project. We altered promoter of gene into EF-1α which would not be silenced in pluripotent stage. There are several ways to convert iPS cells into hepatocytes available. We hope that our device could promote the development and clinical application of iPSC technology.

So... To live or not to live?

We prefer:

To liver or not to live!

Sun Yat-Sen University, Guangzhou, China

Address: 135# Xingang Rd.(W.), Haizhu Guangzhou, P.R.China

Retrieved from "http://2013.igem.org/Team:SYSU-China/Project/Overview"